Trial Profile

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Combination with Serplulimab with or Without Platinum-based Chemotherapy in Selected Subjects with Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tambotatug pelitecan (Primary) ; Platinum complexes; Serplulimab
Indications Nasopharyngeal cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors MediLink Therapeutics

25 Jun 2026 Status changed from recruiting to active, no longer recruiting.
22 Jul 2024 Status changed from not yet recruiting to recruiting.
16 May 2024 Planned initiation date changed from 30 Apr 2024 to 17 May 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com